Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan

BACKGROUND: Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity and utility data for the 21-gene assay (Oncotype DX® Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA) are now available. The objective of this study was to evaluate the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Hideko, Nakagawa, Chizuko, Yamashige, Shinji, Takei, Hiroyuki, Yagata, Hiroshi, Yoshida, Atsushi, Hayashi, Naoki, Hornberger, John, Yu, Tiffany, Chao, Calvin, Yoshizawa, Carl, Nakamura, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165904/
https://www.ncbi.nlm.nih.gov/pubmed/25190451
http://dx.doi.org/10.1186/1472-6963-14-372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165904/
https://www.ncbi.nlm.nih.gov/pubmed/25190451
http://dx.doi.org/10.1186/1472-6963-14-372

Ejemplares similares